4 results about "Chilblains" patented technology

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition and application and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from the following components in parts by weight: 3-35 parts of garden burnet, 2-22 parts of pawpaw, 2-18 parts of radix curcumae, 1-26 parts of radix stephaniae tetrandrae, 2-16 parts of rhizoma atractylodis, 3-13 parts of rhizoma bletillae, 5-23 parts of rhizoma corydalis, 2-20 parts of cortex phellodendri, 1-12 parts of borneol, 25-60 parts of calcined gypsum, 30-70 parts of calamine, 3-18 parts of frankincense, 2-15 parts of myrrh and 2-17 parts of dragon's blood. The traditional Chinese medicine is prepared from the following components in parts by weight: 2-16 parts of hematoxylon, 3-13 parts of rhizoma sparganii, 3-15 parts of notopterygium root, 2-16 parts of pseudo-ginseng and 85-150 parts of sesame oil. The traditional Chinese medicine composition disclosed by the invention is suitable for various long-term non-healing wounds with unknown reasons, such as long-term non-healing wounds caused by postoperative, infection, burn and diabetic foot, and sore and ulcer diseases such as chilblain, ecthyma, bedsore and the like, and has a remarkable curative effect.

The invention belongs to the technical field of daily chemical products, and particularly relates to antibacterial gel and a preparation method thereof.The antibacterial gel is formed by processing main materials and auxiliary materials, and the auxiliary materials comprise, by weight, 50% of deionized water, 10% of cynanchum atratum extract, 10% of wax chrysanthemum extract, 10% of fructus cnidii extract, 5% of mint extract, 5% of purslane extract and 10% of silver ions; the main material is a periplaneta americana extract, and the weight ratio of the main material to the auxiliary material is 3: 100; the product disclosed by the invention has a particularly good effect on vaginitis, colporrhagia, peculiar smell, pruritus and cervical erosion; auxiliary curative effects are achieved on male and female hemorrhoids and male prostate; the wound hemostasis and rapid wound healing effects are obvious; the traditional Chinese medicine composition has a relatively good repairing effect on burns and scalds, red and swollen ulcers, bedsores, chilblain and herpes zoster; the traditional Chinese medicine composition has a good repairing effect on ulcer and ulceration and retina injury caused by diabetic complications.

The present invention relates to the compound of Formula 1 and STING antagonists, for example, systemic lupus erythematosus (SLE), (monogeneic and digeneic) interferon disorders (including STING-associated vascular disorders that develop in infancy (SAVI), Eicardi-Goutier syndrome (AGS), COPA syndrome, and familial chilblain lupus), type 1 interferon disorders with mutations in DNASE2 or ATAD3A genes, age-related macular degeneration (AMD), retinopathy, glaucoma, amyotrophic lateral sclerosis (ALS), diabetes mellitus, obesity, and inflammatory bowel disease. This relates to the use of these as STING antagonists for the treatment of diseases selected from the group consisting of intestinal diseases (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), dermatomyositis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), acute exacerbation of chronic liver failure (ACLF), interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), age-related / muscle disorders, sepsis, heart failure, rheumatoid arthritis and osteoarthritis. JPEG2026510538000418.jpg45150